BlossomHill Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio
BlossomHill Therapeutics, Inc. Common Stock cash flow-to-debt ratio. BlossomHill Therapeutics, Inc. Common Stock (BLSM) has a Cash Flow-to-Debt Ratio of -0.07x as of March 2026, meaning its operating cash flow of $-20.94 Million could theoretically repay 0% of its total liabilities ($295.53 Million) in one year. See BLSM financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of BlossomHill Therapeutics, Inc. Common Stock (2024–2025)
Cash flow-to-debt ratio of BlossomHill Therapeutics, Inc. Common Stock from 2024 to 2025. Historical debt coverage capacity for BlossomHill Therapeutics, Inc. Common Stock across 2 annual periods. Also explore net asset momentum of BlossomHill Therapeutics, Inc. Common St to track the company's year-over-year net asset growth rate.
BlossomHill Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2024–2025)
BlossomHill Therapeutics, Inc. Common Stock cash flow-to-debt ratio by year from 2024 to 2025. Year-by-year debt coverage analysis for BlossomHill Therapeutics, Inc. Common Stock. For the full cash flow conversion analysis, see BlossomHill Therapeutics, Inc. Common St cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.16x | $-46.92 Million | $294.70 Million | ▲ +8.9% |
| 2024 | -0.17x | $-31.42 Million | $179.66 Million | — |